Hyperthermia in cervical cancer – current status by Burchardt, Ewa & Roszak, Andrzej
reports of practical oncology and radiotherapy 2 3 ( 2 0 1 8 ) 595–603
Available online at www.sciencedirect.com
ScienceDirect
journa l homepage: ht tp : / /www.e lsev ier .com/ locate / rpor
Review
Hyperthermia in cervical cancer – current status
Ewa Burchardta,∗, Andrzej Roszaka,b
a Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Centre, Poznan, Poland
b Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland
a r t i c l e i n f o
Article history:
Received 31 October 2017
Received in revised form
19 February 2018
Accepted 25 May 2018






a b s t r a c t
Background: This article reviews the salient features of recent results of clinical studies. It puts
a special emphasis on technical aspects, mechanisms of action together with radiotherapy
and chemotherapy and points out areas for additional investigation.
Aim: To present the current state of knowledge on hyperthermia (HT) and to highlight its
role in the treatment of cervical cancer.
Materials and methods: The literature on the clinical use of combined hyperthermia for cer-
vical cancer was analyzed. Clinical outcomes together with the technical aspects and the
role of HT were also evaluated.
Results: Clinically randomized trials have demonstrated benefit including survival with the
addition of hyperthermia to radiation or chemotherapy in the treatment of cervical cancer
without significant acute or late morbidities. The technological advances have led to an
effective and safer treatment delivery, thermal treatment planning, thermal dose monitor-
ing and online adaptive temperature modulation.
Conclusions: Due to rapid development over the last decade of hyperthermia systems and
new studies at the basic science and clinical level, the perception of hyperthermia as a part
of multimodality treatment in cervical cancer has been changed. However, there is still a
need for multicentre randomized clinical trials.
© 2018 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
1. Introduction
Cervical cancer represents a serious oncology problem
in developing countries where 85% of 500,000 cases are
diagnosed worldwide. Cervical cancer (CC) accounts for
approximately 13% of all cancer cases in women.1 The high-
est risk is observed in Africa and South America.1,2 The global
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incidence have been decreasing for more than a decade in
developing countries as a result of both better diagnosis and
better prevention by using vaccines against human papillo-
mavirus (HPV) which are increasingly available. But still, with
cancer diagnosed at a regionally advanced stage, prognosis is
much worse. In this respect, little progress has been observed
in treatment results in recent years. Approximately 54% of
patients worldwide continue to be diagnosed at a locoregion-
ally advanced or metastatic stage and the five-year relative
survival (relative survival is an estimate of the percentage
of patients who would be expected to survive the effects of
their cancer) for regionally advanced cervical cancer is 57%.2
Radiochemotherapy (RTCT) is a standard procedure in locally
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advanced cervical cancer (LACC). That treatment modality
is commonly accepted worldwide according to guidelines of
many oncology societies, based on randomized study results
that have illustrated its advantages as compared to radiother-
apy alone.3–7 Hyperthermia (HT) in the treatment of LACC
improves the results of treatment in many studies and analy-
ses, but it is still rarely used by oncologists.
The aim of this article is to present the current state of
knowledge on HT and its role in the treatment of cervical
cancer.
2. How does HT work?
HT is an intended artificial increase of temperature over the
temperature of human body within the range of 39–43 ◦C.
Many laboratory tests have shown how hyperthermia acts
on cells and tissues. Certainly, these should not be imple-
mented directly to clinical practice, but they do indicate ways
and points of reference for HT that enable us to obtain an
additive effect together with RT and CT. Temperature can be
raised by applying various electromagnetic waves (including
microwaves, radio waves) or acoustic waves (ultrasound). One
of the new developments in this area are works on the use
of nanoparticles which, when evenly spread in the tumour,
may distribute heat homogeneously. However, the source of
energy will depend primarily on the type of cancer and its loca-
tion (superficial vs. deep). Local and regional hyperthermia is
used in the treatment of cervical cancer. The former is applied
in intracavitary and interstitial delivery of heat for tumours
of up to 5–6 cm in diameter. That method is now most com-
monly combined with interstitial brachytherapy. The other
method involves the increase of temperature in a large vol-
ume of tissue, e.g. in the pelvis region.8 Regional hyperthermia
also includes HIPEC, during which a cytostatic is administered
intraperitoneally under conditions of increased temperature.
The other kind of therapy is effectively used against cancers
located within the peritoneal cavity, such as pancreatic or col-
orectal cancer.9,10 Currently, in locoregional deep HT systems,
particularly in LACC, the target volume is treated with exter-
nal HT using electromagnetic waves. Some progress has also
been achieved in high focused ultrasound (HIFU).
The hyperthermia-induced cytotoxic reaction is mainly
targeted to proteins. HT reinforces and complements the cyto-
toxic effect of radiotherapy. This arises from the fact that cells
in the S phase are radioresistant but sensitive to HT. Similarly,
in anaerobic conditions with low pH, the resistance to radio-
therapy grows, but not to HT. Pathogenesis of anoxic areas in
tumour is of a multivariate nature, abnormal microcirculation
being one of the reasons. HT effects include increased per-
fusion, induction of apoptosis, e.g. through the BAX protein,
reoxidation.11–13 Finally, HT inhibits the repair of both sub-
lethal and potentially lethal damage by deactivation of key
DNA repair pathways.14
A very interesting and beneficial mechanism triggered by
HT within the scope of clinical use, i.e. 40–42 ◦C, is the modu-
lation of the immunological system.15,16 HT causes the growth
in the number of Heat Shock Protein 70 (HSP70) on the surface
of the cells and in release of HSP70 from tumour cells, which
is a call sign for activated NK cells. Dendritic cells are acti-
vated through the class I MHC complex to migrate to lymph
nodes where they initiate lymphocyte T cytotoxicity towards
HSP presenting cells. HT boosts the maturation and migration
of dendritic cells and the release of cytotoxins.17,18
Chemotherapeutics may act independently, additively or
synergistically in combination with HT. The first group include
5-flurouracil, methotrexate, taxans. Among drugs which cause
the cell survival curve to change with the growing temperature
with an additional cytotoxic effect are doxorubicin, cyclophos-
phamide, ifosphamide, gemcitabine. In the case of cisplatin
(CCDP) and analogues (e.g. carboplatin), a strong effect of
hyperthermia on cytotoxicity has even been demonstrated
in relatively low temperatures (40.5 ◦C). The group of drugs
producing a synergistic effect also includes bleomycin.19 The
synergy involves an enhanced uptake of the drug in cells,
increased production of radicals, increased DNA damage and
inhibition of DNA repair, as well as reversal of drug resistance
mechanisms.10,20
There have been extensive studies to assess the pre-
treatment HPV levels and how they change during radio-
therapy in head and neck cancers. It turned out that similar
observations apply to cervical cancer. HPV titer reduction dur-
ing treatment is a survival predictor, while retaining infection
leads to cancer growth.21 In vitro studies have shown that the
temperature of 42 ◦C degrades protein E6 (oncoprotein, early
protein 6 E6) which connects with p53 and mediates its degra-
dation. Therefore, neutralization of E6 protein may prove a
promising treatment method to eliminate HPV-positive can-
cer cells, thus preventing the E6-p53 complex from forming
and enabling p53-dependent apoptosis and G2 phase arrest.22
3. HT treatment planning and Quality
Assurance
Hyperthermia as a method of cancer treatment has often been
ignored and avoided. The main factors to hinder clinical use
included difficulties in reproducing appropriate temperature
in the tumour mass and surrounding tissue, difficulties in pre-
cise temperature measurement and, frequently, the lack of
protocols of HT used. Due to the diversity of equipment used to
increase temperature in the body, direct comparative analysis
between treatment centres is often impossible. Measurements
during HT are significant.
The technological progress has now enabled the use of
state-of-the-art methods, such as fluency maps for temper-
ature distribution at the site of locoregional hyperthermia,
specification of temperature at particular regions. Works are
also being carried out to provide possibilities to monitor areas
receiving adequate dose in Gy and corresponding tempera-
ture measurement – the same as during RT planning. Thus,
temperature distribution can be planned in 3D and calculate it
in real time, preferably with MRI monitoring.17 Requirements
for hyperthermic treatment planning have been gathered in
the Quality Assurance Guidelines.23,24 The T90 indicator is a
relevant parameter in optimizing treatment. It is temperature
exceeded in 90% of the target volume surface. That parameter
has been proved to correlate with clinical outcome. With
precise knowledge of temperature levels, treatment plans
can be adapted based on expected enhancement effect. In
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bimodality treatment, the enhancement effect resulting from
the addition of HT can then be calculated and the whole treat-
ment process optimized: RT dose combined with temperature
measurement. In order to quantify the synergistic effect of
heat and radiation, the Thermal Enhancement Ratio (TER)
is used. TER defines the amount of thermal radiosensitivity
growth by survival fractions (SFs) after a stand-alone radio-
therapy fraction and combined with hyperthermia.25 The
degree of cytostatic radiosensitivity may also be represented
as TER which is expressed by the cell survival rate in temper-
ature higher than a constant level for do a specific dose of the
drug.26 Many studies have demonstrated a relation between
temperature dose and effect.27 DFSs are higher if CEM43T90
(≥1 min). If such parameters have been achieved, the addition
of HT effectively improves treatment outcomes. Such results
were achieved in a Japanese study where temperature control
parameters were among study priorities.28 Similar results
were achieved for breast cancer where better LC was only
found in patients in whom higher temperatures were gener-
ated inside the tumour.29 Harima and colleagues took note
of a very high relevance of defining right temperature at each
application of HT. In their reports, Harima has consistently
analyzed, presented and implemented the treatment parame-
ters. Certainly, those parameters include all the elements that
affect HT in combination with RT and CT, such as increase
in oxidation and perfusion during HT, importance of the
duration of HT or the number of applications.30,31
3.1. Evaluation of results of HT and RT
The publication of a prospective multi-centre randomized
study on the effects of HT added to radiotherapy (RT) in pelvic
cancers in The Lancet, in 2000, marked a breakthrough in
treatment results of LACC.32 The method was regarded as par-
ticularly promising in the treatment of LACC. However, up to
date, HT remains to be a controversial matter of debate.
In the aforementioned Dutch Deep Hyperthermia Trial
(DDHT), a group of patients treated in 1990–1996 was charac-
terized by large tumour >60 mm in diameter, i.e. highly locally
advanced, performance status of World Health Organization
(WHO) 0 or I, mean age 51 years, haemoglobin levels (Hgb)
both < and >7 mmol/L. Remarkable overall survival (OS) results
of 27% vs. 54%, improved local control (LC) from 41% to 61%
at three-year follow-up of patients treated with hyperther-
mia added to radiotherapy were also confirmed at 12-year
follow-up: OS of 20% vs. 37% and LC 37% vs. 56%, respectively
(Table 1).32,33 No statistically significant difference in toxicity
was demonstrated between the HT and non-HT groups.32,33
The Dutch researchers also analyzed a group of patients
from the following years. A group of 378 patients included in
that study were at a worse condition according to the WHO
scale (WHO 0–WHO III) and had larger tumours (mean diame-
ter of 9 cm vs. 7.6 cm in DDHT). LC, which is the first condition
for recovery and one of the primary endpoints in that study,
was 53% after 5 years, thus confirming beneficial treatment
results with HT added to RT. Five-year OS was 40% in the whole
study group. Importantly, the treatment was found to cause
no additional early or late toxicity that might arise from HT.
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Japan researchers reported the results from a study of 40
patients with LACC (only FIGO IIIB) treated with RT or RT+HT.
They observed a difference in 3yrOS 48% for RT and 58%
for RTHT, but it was not statistically significant.35 However,
they observed significant improvement in LC and complete
response (CR) 50% and 49% for RT compared to 80% and 80%
for RT+HT, respectively (Table 1). Toxicity was not significantly
different between treatment groups.35
Vasanthan et al. from India reported the results from multi-
centre study in 110 patients with CC in stage FIGO IIB-IVA. No
significant difference was observed both in LC and OS (Table 1).
The quality of HT (partial intravaginal HT) described in this
work was not sufficiently reported and explained.35,36 The
quality of HT probably played a major role and influenced the
results of RT+HT in this trial.37
The position of HT as a method to greatly improve RT
results in cervical cancer was further reinforced by the
Cochrane Database analysis. It confirmed a complementary
role of HT in combination with RT. RT supplemented with HT
results in significantly statistically higher CR with relative risk
of 0.56, lower local recurrence (LR) with Hazard Ratio (HR) of
0.48 and better OS with HR of 0.67. No additional toxicity was
found. While many studies included in the analysis came from
single centres, FIGO IIIB patients were in majority in each of
them.38
3.2. Evaluation of results of HT and RTCT
For more than a decade, radiochemotherapy (RTCT) has been a
standard procedure in LACC. That treatment modality is com-
monly accepted worldwide according to guidelines of many
oncology societies, based on randomized study results that
have illustrated its advantages as compared to radiotherapy
alone.3–7 Meta-analysis confirmed that treatment involving
RTCT delivers better outcome than radiotherapy alone.39 As
the above studies differed from one another and a number
of questions were raised as to their interpretation, another
meta-analysis was performed to confirm that the improve-
ment in five-year OS is 3% in patients with FIGO III–IVA and 7%
in patients with IIB. At the same time, both reviews revealed
a high growth of hematologic and gastrointestinal toxicity.40
The US studies received a wide coverage and, according to
the National Cancer Institute guidelines, were implemented
into clinical practice to change the existing course of action.
Inclusion of cytotoxic agents into the standard management
of cervical cancer requires the involvement of chemothera-
peutic department, which are already there in every oncology
centre, and does not require any additional equipment, infras-
tructure or investment.
However, considering the increased toxicity and still not
fully satisfactory treatment outcomes, studies were initiated
on a ‘trimodality treatment’. Various mechanisms of action
and toxicity profile encourage HT to be combined with both RT
and simultaneous chemotherapy. A non-randomized prospec-
tive study including 69 patients from the US, Norway and
the Netherlands treated with cisplatin-based RTCT adminis-
tered weekly with HT applied once a week showed the safety
of such a modality, and the 5-year treatment results were at
least comparable to those achieved with a classic RTCT. Five-
year relapse-free survival 57.5% (95% confidence interval (CI):
46.6–71.0) and five-year OS 66.1% (95%CI: 55.1–79.3).41 To add
a missing component of the above investigation, a Japanese
group performed a randomized multi-centre clinical trial of
RTCT + HT vs. RTCT alone. The trimodality was found to show
a tendency towards better treatment outcomes, but without
a statistically significant p-value. Again, that study did not
demonstrate any increase in HT-induced toxicity. In the logis-
tic regression analysis, the HT group achieved CR more often
(88%) than the non-HT group (77.6%, Table 2).28 However, as
the authors indicate, the study inclusion criteria were quite
restrictive. Patients with metastatic lymph nodes in the aorta
region and haemoglobin level ≤10 g/dL were not included.
Both factors are associated with a lower survival rate. This may
also account for very good treatment outcomes in the RTCT
arm. This should, consequently, lead to the change of initial
statistical assumptions and a much larger group of subjects is
needed to detect a statistically significant difference.28
In 2016, Lutgens et al. reported their results obtained
in RADCHOC study (randomized control trial) including 87
patients with LACC. Median follow up was 7.1 years.41 The
study compared RTCT vs. RT+HT, but it was closed prema-
turely after enrolling 87 of the 376 planned patients. The
results suggested comparable outcomes in terms of LC 78%
vs. 80% and OS 69% vs. 69% at 5-years (Table 2). RADCHOC
was designed to establish if radiotherapy combined with
hyperthermia (RT+HT) should be preferred in bulky and/or
FIGO-stage III. However, only 19% of patients in the RTCT
and 24% in the RT+HT arm had tumours >6 cm.42 RADCHOC
trial did not provide an answer to the question if RTCT or
RTHT should be preferred but it suggested that RT-HT pro-
vides an effective alternative radical treatment even for small
tumours.42
A very important meta-analysis has recently been pub-
lished in this subject matter. Data et al. on the comparison of
RTHT vs. RT, RTCTHT vs. RT have been updated. A higher per-
centage of patients treated with RTHT and RTCTHT achieved
CR and HTRT delivered higher OS as compared to RT alone (no
such comparison was made for RTCTHT vs. RT). Grade III–IV
acute toxicity and late complications were comparable.43
Network meta-analysis was also used which, unlike classic
meta-analysis, enables an indirect and direct analysis of more
treatment methods. First, when comparing RTCT vs. RTCTHT,
RT vs. RTCTHT, RT vs. RTCT, and RTHT vs. RTCTHT in the
context of CR and OS, RTCTHT was found to be much more
beneficial than RT and RTCT. Second, when comparing RTHT
and RTCT with a network meta-analysis method, it was shown
that CR RTHT performed better; however, in terms of OS both
methods are comparable. The use of chemotherapy is asso-
ciated with increased treatment toxicity, an effect that is not
observed with HT.43
A particular case is that of HT combined with brachyther-
apy. Such treatment was carried out in Warsaw to check if
interstitial brachytherapy (BT) combined with HT improves
local control or disease free survival (DFS, Table 2).44 The addi-
tion of HT was not observed to affect treatment outcomes.
HT was only added to BT performed once a week following a
completed stage of teleradiotherapy.44 With HT used in that
model, the high temperature’s range of action is very limited,
which causes the activity of HT to be limited, too. Further-































































































































































































































































































































































































































































































































































































more the tumour is much smaller with fewer hypoxic foci.
Previous studies have demonstrated the effectiveness of HT,
particularly in primary tumours of large volume.
3.3. Evaluation of results of HT and chemotherapy for
recurrent or metastatic CC
The outcome of treatment of recurrent or metastatic CC
remains particularly poor. A probable reason for this is the
decreased blood flow to the organs caused by vascular changes
after RT. The most widely used drug is cisplatin alone or in
combination with other drug topotecan or paclitaxel with
response rate around 33%.45,46 The addition of bevacizumab
to chemotherapy increased OS (17 vs. 13 months) and resulted
in higher response rates (48% vs. 36%). It was also associated
with an increased toxitcity.47
The therapeutic potential of HT with chemotherapy in
recurrent or metastatic CC was recognized at the end of last
century. The results were confirmed by Richel et al. in 2004 in
a phase II study. They observed 25 patients with recurrent or
metastatic CC who had been treated with cisplatin monother-
apy and whole body HT. CT+HT yielded very good treatment
results i.e. CR ∼5% and partial response (PR) ∼28%, stable dis-
ease (SD) ∼43%, 1yr OS ∼36% (Table 3).48 In addition, Franckena
et al. presented more promising results in 2007 after the anal-
ysis of a group of 47 patients with recurrence or metastatic
CC. The patients were treated with cisplatin and HT. They
achieved 55% response rate (PR+CR) and 8 month median OS
(Table 3).49 On the other hand, the results presented seven
years later by the same research group were completely dif-
ferent. Heijkoop et al. presented a group of 38 patients with
recurrent or metastatic cervical cancer after RTCT with cis-
platin. Median follow-up was 6.5 months.50 The patients were
treated with cisplatin and HT. Overall response rate (PR+CR)
was 14% and 1 year OS was 23% (Table 3). The authors of the
study do not recommend this treatment for recurrence of CC
after RCTH.50
Recently, Lee et al. from South Korea have presented
the results of treatment of patients with regional recur-
rence of CC. They administered chemotherapy with cisplatin,
carboplatin, paclitaxel, 5-flurouracil and used modulated
electro-hyperthermia in order to avoid the drawbacks of
conventional electromagnetic heating.51 The modulated
electro-hyperthermia is designed to enhance the thera-
peutic response by heating selectively malignant tumours
and tumour cells by modulated delivery of short radiofre-
quency waves of 13.56 MHz. This method of HT heats the
malignant cell membrane, induces apoptotic cell death and
promotes immunological response.52–54 Median follow up was
11 months for the chemotherapy group and 13.5 months for
chemotherapy with the HT group. The overall response rate
(CR+PR+SD) was significantly higher in the group of patients
who received chemotherapy and HT than in that who received
chemotherapy alone: 72% vs. 40%, respectively.51 The study

































Table 3 – Characteristics of the studies of HT and CT as palliative approach in recurrent CC.

















Richel et al., 200448 Phase II 21 (25) Recurrent or
metastatic CC
7.5 (OS) CT (CDDP)+Whole body PD ∼ 24% SD ∼ 43% PR ∼ 28% CR ∼ 5% 1yrOS ∼ 36% 1yrPFS ∼ 16%
Franckena et al.,
200748
Phase I/II 47 Recurrent or
metastatic
(n = 8) CC after
CT (n = 12), after
HT (n = 8)










6.5 CT (CDDP)+HT PD – 51% SD – 35% PR – 11% CR – 3% 1yrOS – 23% 2yrOS – 4%


























∼1yrOS 75% ∼1yrOS 86%(SS)
CR: complete response; CT: chemotherapy; FP: cisplatin and 5-fluorouracil; HT: hyperthermia; N: number; NS: not significant; OS: overall survival; RT radiotherapy; SD: stable disease; PD: progressive
disease; PR: partial response; SS: statistical significant; TC: paclitaxel and carboplatin; TP: paclitaxel and cisplatin; yr: years.
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3.4. State of the art and future perspectives
As technology advances, HT enters a period of rapid devel-
opment gaining more and more acceptance of the clinical
community. The perception of HT in cancer treatment has
been changed.
A very strong emphasis is put on the quality of HT used.
Optimal treatment model for LACC still remains an open ques-
tion. Despite so much evidence of efficacy and favourable
outcomes without toxicity, HT is yet to be included in the
NCCN recommendations for cervical cancer. It seems that now
it is time to separate more specific groups of patients who
could benefit the most from the addition of HT. Many fac-
tors need to be taken into account, as the disease responds to
treatment in different ways depending on the stage. Prognosis
for patients with metastatic lymph nodes of the aorta region
(PALN+) is quite different from those with FIGO IB/IIA cancer.
The HPV status, which has not been taken into consideration
so far, is very important as it constitutes an independent prog-
nostic factor. The main issue for investigators from centres
having HT equipment is a poor recruitment of patients for
studies. Another element to remember is the aforementioned
diversity of HT equipment and quality of treatment delivered.
Thermal parameters, length of application, frequency of use,
intervals in combination with RT or CT are factors that affect
effectiveness and, consequently, the results and outcomes.
Currently, two study projects recruiting LACC patients are
open at ClinicalTrials.gov. One of them relates to the combi-
nation of HT with interstitial brachytherapy, and the other to
cervical cancer spread beyond the pelvis in combination with
HIPEC and chemotherapy. The third study is waiting for the
recruitment to open for patients with cervical cancer but also
diagnosed sarcoma of the extremities, in combination with
MR-HIFU. When this article is being written, there is no reg-
istered open randomized trial concerning the combination of
RTCT and HT, and RT and HT.
4. Conclusions
HT combined with other treatment modalities is part of a mul-
tidisciplinary oncological management in CC and should be
more often used by the clinician. HT requires very reliable
quality assurance. RT and HT is better than RT alone in pri-
mary treatment of LACC. In addition, RT and HT is a very good
option for the primary treatment of LACC in patients with con-
traindications for RTCT due to a different toxicity profile. In
the treatment of regional recurrence and metastatic CC after
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